Glucantime is a highly specialized systemic medication primarily used for Leishmaniasis, a parasitic disease. Its use is focused on addressing the symptoms stemming from the parasitic infection and is relevant for easing the symptoms associated with the complex, severe infection. Meglumine antimoniate is centrally relevant for the management of the three main forms of the disease: Visceral Leishmaniasis (kala-azar), Cutaneous Leishmaniasis, and Mucocutaneous Leishmaniasis.

The medication is generally used for conditions where parasitic activity causes significant systemic or tissue damage. The primary goal of this therapy is to support the management of the severe infection, particularly when symptoms interfere with daily functioning.

Treating Visceral Leishmaniasis (Kala-Azar)

Glucantime is commonly used as a foundational therapy for Visceral Leishmaniasis (VL). This treatment may assist with managing profound systemic symptoms, including persistent, high fever, organ enlargement, and debilitating anemia and weakness. Its main purpose is to support the management of the severe, systemic infection and supports the patient during this difficult symptomatic phase.

Quick Fact: Relief for Systemic Imbalance Glucantime may assist in addressing symptoms related to systemic imbalance, such as fever and organ-specific functional stress caused by the parasite.

Healing Complex Skin and Mucosal Destruction

The medication is commonly used for managing complex Cutaneous and Mucocutaneous Leishmaniasis when lesions are widespread or fail to heal spontaneously. In these contexts, Glucantime may assist with the healing process of chronic skin ulcers, may help address the destructive spread of the parasite, and contributes to easing the risks associated with tissue damage and permanent disfigurement.

Official Population Eligibility for Glucantime

Glucantime (meglumine antimoniate) is absolutely contraindicated for use in any population with a known hypersensitivity to the active substance or any of its excipients, including sulphite.

For other populations, official regulatory criteria impose strict conditional restrictions primarily linked to organ function and reproductive status:

• Organ Function Restrictions: Use requires caution, mandatory monitoring, and potential dose reduction for patients with pre-existing hepatic function abnormalities or renal function abnormalities. The presence of pancreatic disease also warrants caution.
• Cardiovascular Restrictions: The medicine is restricted for patients with existing heart disease or those with risk factors for QT interval prolongation, requiring special caution and cardiac monitoring.
• Reproductive Status: The medicine must not be used during pregnancy except under highly restricted, life-threatening conditions where the benefit outweighs the potential fetal harm. Use is not recommended for women who are breastfeeding during treatment.

Usage is generally permitted for adult, adolescent, and pediatric patients. However, in some countries, such as the United States, the drug is not commercially approved by the national authority, and access is typically limited to an individual Investigational New Drug protocol.

Interactions with other medicines and products

Glucantime's official regulatory information outlines two key categories of interactions: additive cardiac effects and a mandatory administration restriction. The interaction profile is defined by pharmacodynamic concerns rather than metabolic pathways.

Pharmacodynamic Interactions

The most clinically significant interaction documented is a pharmacodynamic effect involving the heart's electrical activity. Co-administration of Glucantime (meglumine antimoniate) with other medicinal products known to prolong the QT interval carries an additive risk of severe arrhythmia. Regulatory documents specifically identify several classes of drugs that interact via this mechanism, including certain Class IA and III antiarrhythmics, macrolides, tricyclic antidepressants, antipsychotics, and other antiparasitic agents.

Population-Dependent Risk

The severity of this cardiac interaction may be heightened in specific populations. The official prescribing information notes that increased caution is necessary when the medicine is used in the presence of uncorrected electrolyte imbalances, such as hypokalemia or hypomagnesemia, or in patients with pre-existing heart conditions, including congenital long QT syndrome or prior myocardial infarction.

Administration Restriction

Glucantime's interaction profile also includes a mandatory administration rule related to physical compatibility. Due to the absence of compatibility studies, the injection solution must not be physically mixed with any other medication in the same syringe or infusion line. Regulatory records do not document any formal pharmacokinetic interactions, such as those involving CYP enzymes or drug transporters.

Prodrug Activation and Targeting Parasite Redox Systems

The administered pentavalent antimony ( Sb^ V) acts as a prodrug, undergoing reduction primarily within host macrophages to the active species, trivalent antimony ( Sb^ III). This Sb^ III selectively binds to and depletes essential thiol compounds inside the parasite, most importantly inactivating the unique enzyme Trypanothione Reductase (TryR). This molecular interaction contributes to the functional collapse of the parasite's defense against internal oxidative damage.

---

Metabolic Starvation and Immune Function Modulation

Simultaneously, the active antimony compound interferes with the parasite’s bioenergetic pathways by inhibiting enzymes in glycolysis and fatty acid oxidation, causing severe depletion of ATP levels. The resulting metabolic collapse and oxidative stress activate pathways leading to mitochondrial depolarization and parasite cell destruction. The drug also modulates the host's immune system by enhancing the microbicidal activity of infected macrophages, promoting a more robust host contribution to parasite reduction.

Glucantime is formulated as a solution for injection and is administered through parenteral routes, including intramuscular (IM) and intravenous (IV) injection for systemic infection, or via intra-lesional (IL) injection for localized skin lesions. Dosing is calculated strictly on the amount of pentavalent antimony (Sb^V) contained in the solution, not the total salt weight.

The standard systemic dose for both adults and children is 20 mg of Sb^V per kilogram of body weight, administered once daily. This dose does not exceed a maximum of 850 mg of Sb^V per day. For intravenous use, the medicine must be diluted in 50 ml of a suitable solution, such as normal saline, and administered slowly over a minimum of 10 minutes.

Treatment involves consecutive daily injections, with typical courses lasting approximately 20 days for Cutaneous Leishmaniasis and 28 days for Visceral and Mucosal Leishmaniasis. Administration must be continued until the endpoint, characterized by the disappearance of the parasite in clinical samples, plus a few days beyond. Doses are typically reduced in patients with pre-existing hepatic or renal function abnormalities. Furthermore, the solution is restricted from being mixed with other medications due to incompatibility guidelines.

Glucantime: Overview of Studies

Evidence for use in Visceral Leishmaniasis (VL) / Kala-Azar

Glucantime was studied for use in Visceral Leishmaniasis (VL), often called Kala-Azar, in established study designs, including Randomized Controlled Trials (RCTs) and specialized Non-Inferiority Trials. The research included adult and adolescent populations. Studies explored how symptoms change over time and evaluated outcomes reflecting daily functioning or activity level.

The outcomes monitored in these trials were primarily focused on measurements of parasite-free status, described in research as the Final Cure Rate, and the patterns of disease recurrence, described as the Relapse Frequency. Research also examined clinical indicators, such as the time required for fever resolution.

Evidence for use in Cutaneous Leishmaniasis (CL)

Glucantime was studied for use in Cutaneous Leishmaniasis (CL). The evidence base includes multiple Randomized Controlled Trials (RCTs). The studies explored different methods of administering the medicine, including comparing systemic injection with direct injection into the lesion itself (intra-lesional administration).

The main outcomes monitored included the time required for lesion closure (Time to Healing) and the extent of physical lesion resolution (Definitive Cure) at specific time points. Research has documented different patterns of outcome measurement when comparing adult versus pediatric populations, indicating a need for cautious interpretation in some subgroups.

Documented Evidence Gaps and Areas of Uncertainty

The research base highlights areas where certainty remains low. One key limitation is the existence of regional variability in reported outcomes. Data for certain groups, such as specific age ranges or individuals with rare co-morbidities, remain insufficient. Evidence quality varies across studies, particularly older trials, due to documented high levels of heterogeneity. Research is ongoing to address these limitations.

Key Studies & References

1. Effectiveness of Short-Course Meglumine Antimoniate (Glucantime®) for Treatment of Visceral Leishmaniasis: A 13-Year, Multistage, Non-Inferiority Study in Iran

Common questions about Glucantime (FAQ)

---

Q: Is Glucantime the same thing as meglumine antimoniate?

Yes, they are essentially the same. Meglumine antimoniate is the official name of the active substance contained in the medicine Glucantime. This substance is recognized by international bodies, such as the World Health Organization (WHO), for its intended use.

Q: Why do official sources sometimes refer to Glucantime as a pentavalent antimonial?

Official documents use this term because the drug's active component is pentavalent antimony ( extSb^ extV). This is the metallic element that gives the medicine its specific action. The term 'antimonial' simply refers to the class of drugs that contain this element.

Q: How is Glucantime described in official sources for people with kidney problems?

Official prescribing information requires careful management for people with kidney concerns. Regulatory guidelines state that the dose must be reduced in patients with pre-existing renal (kidney) function abnormalities. Monitoring of kidney function is also typically advised by healthcare professionals during the course of treatment.

Q: What do official documents say about combining Glucantime with other anti-infective agents?

Regulatory information advises caution against using Glucantime with certain other medicines, particularly those that can cause a change in heart rhythm, known as QT prolongation. Furthermore, the Glucantime solution is restricted from being mixed with any other medicine in the same syringe due to known chemical incompatibilities.

Q: What kind of studies have been done on Glucantime?

Official publications, including those from the World Health Organization (WHO) and the National Institutes of Health (NIH), frequently cite clinical trials and studies. These studies examine the drug's effectiveness and overall safety profile, particularly for treating the various forms of leishmaniasis.

Q: How long does Glucantime stay in the body after the treatment is over?

Pharmacokinetic data from regulatory documents indicate that the body processes the active substance quite rapidly. Over 80% of the pentavalent antimony is typically excreted unchanged in the urine within 6 hours of administration.

Q: What are the general expectations about how a person may feel during treatment with Glucantime?

Based on official documents describing common side effects, many patients report feeling a general sense of malaise (discomfort), headaches, and anorexia (loss of appetite). These are some of the frequently reported effects.

Q: Is it normal to feel tired while undergoing treatment with Glucantime?

The official list of commonly reported adverse effects includes a feeling of general malaise and muscular weakness. These effects, described in the regulatory summary, may contribute to a feeling of tiredness during the course of treatment.

Q: What are the most commonly mentioned side effects of Glucantime in official documents?

According to the official product information, the most frequently reported side effects are headaches and anorexia (a significant loss of appetite). More detailed information on all possible side effects is found in the main 'Possible side effects' section.

Q: Are there restrictions on who can use Glucantime based on age?

Official dosing summaries show that the standard systemic dose is applicable for both adults and children. Eligibility and suitability for treatment are determined by a healthcare provider based on the specific condition and the patient’s health status.

Q: What has official research indicated about the use of Glucantime in children?

Official dosing guidelines and international health organizations support the use of Glucantime in children. The standard systemic dose is defined for use in both adults and children.

Q: Is Glucantime described as being used for any conditions other than the main one listed?

The drug is officially indicated for the treatment of various forms of leishmaniasis. This includes visceral (internal), cutaneous (skin), and mucocutaneous (mucous membrane) forms of the disease.

Q: What is the official classification of Glucantime regarding pregnancy risk?

Glucantime is generally not recommended during pregnancy because the drug is associated with embryolethal effects and developmental delays in animal studies at high doses. Official guidelines note that administration is generally considered only when a doctor determines that the potential benefit justifies the risks.

Q: What should be known about the safety warnings for Glucantime regarding the heart?

Official warnings note that Glucantime can cause changes in heart rhythm, including QT prolongation and severe arrhythmia (an irregular heartbeat). Due to these risks, monitoring of the ECG (electrocardiogram) is advised throughout treatment, particularly for those with pre-existing heart conditions.

Q: Are there different forms or strengths of Glucantime available in different countries?

The composition most commonly referenced in international supply documents, such as the UNICEF Supply Catalogue and European regulatory documents, is the 1.5 ext g in 5 ext ml solution for injection.

Q: What is the reason Glucantime is not available as a standard prescription in some regions?

In the United States, for example, Glucantime has not undergone the standard commercial approval process and is not commercially available. It is only accessible via an Individual Investigational New Drug (IND) protocol through the FDA for patients who require it.

Q: Are there any common foods or drinks that should be avoided when taking Glucantime?

Regulatory advice does not specify common foods to avoid, but it does note that a high-protein diet should be administered throughout the course of the Glucantime treatment.

Q: What information is available about the long-term effects of Glucantime?

Standard regulatory documents focus mainly on immediate and short-term safety. Preclinical data available in the literature address potential embryolethal and developmental effects in animals but do not provide an explicit summary of long-term effects on the body in the standard human-use documents.

Q: Is Glucantime considered a broad-spectrum anti-infective treatment?

No, official regulatory documents indicate that Glucantime is specifically indicated for various forms of leishmaniasis. It is categorized as an antiprotozoal agent, rather than a broad-spectrum anti-infective used for many different types of infections.

Q: Where can I find the official drug monograph for Glucantime?

The official document containing the most complete and regulated information is the Summary of Product Characteristics (SmPC). This document can typically be found on the websites of government drug regulatory agencies, such as those in Europe.

Q: Do studies suggest Glucantime works immediately, or does it take time to build up in the system?

While the active substance is rapidly cleared from the body—with a short elimination half-life—the standard course of treatment is not short. Treatment is given for an extended period, such as 20 or 28 consecutive days, to reach a definitive clinical endpoint.

Q: What are the conditions under which Glucantime is supplied as described by official bodies?

Glucantime is internationally recognized and is included on the World Health Organization's List of Essential Medicines (EML). This means the WHO considers it among the minimum essential medicine needed for a basic healthcare system.

Q: What has the research evidence indicated about the effectiveness of Glucantime?

Published research cited by global health bodies indicates that Glucantime has demonstrated positive outcomes in clinical trials for the officially indicated conditions.

Q: Can Glucantime be used by individuals who have certain pre-existing liver conditions?

Official prescribing information requires that the dose be reduced in patients with pre-existing hepatic (liver) function abnormalities. Monitoring of liver function is generally advised by medical staff throughout the treatment course.

Q: What is the information available about Glucantime's chemical structure?

The active substance in Glucantime is meglumine antimoniate. This compound is a chemical combination of N-methyl-D-glucamine and pentavalent antimony ( extSb^ extV), which is the therapeutic component.

Q: Are there specific official guidelines about driving or operating machinery while on Glucantime?

Some official regulatory documents state that the effects of Glucantime on the ability to drive and use machinery are 'Not applicable'. This suggests the document states there is no known impact on this ability.

Q: How do official sources describe the proper way to handle Glucantime?

The medicine is supplied as a solution for injection in small containers called ampoules. Official documents specify that for intravenous use, the medicine must be diluted in a suitable solution, such as normal saline.

Q: What has been officially stated about Glucantime and mental health side effects?

Regulatory side effect lists report adverse reactions in the central nervous system, which may affect mood or thought processes. The most common effect reported is headache, which is listed as a very common adverse reaction.

Q: Is Glucantime only used in specific geographic areas?

Official reports indicate that the medicine is primarily used and available in areas where the disease is endemic, such as Southern Europe and Latin America. It is noted that it is not commercially available in all countries, such as the United States.

Q: What does 'contraindicated' mean in the context of Glucantime use?

A contraindication is an official statement that a drug should not be used under certain circumstances because the risks outweigh the benefits. For Glucantime, regulatory documents list a known hypersensitivity (allergy) to the active substance or any of its ingredients as a contraindication.

Q: Can people who are immunocompromised use Glucantime?

Regulatory-cited clinical guidelines from the National Institutes of Health (NIH) address the use of Glucantime. These guidelines specifically discuss the treatment of leishmaniasis in people with HIV/AIDS, who are often immunocompromised.

Q: What are the typical storage conditions for Glucantime as described in the packaging?

International supply and regulatory documents describe the need for proper storage. The product should generally not be stored above 30°C (86°F).

Q: What is Glucantime's designated use by international health organizations like the WHO?

The World Health Organization (WHO) includes Glucantime on its List of Essential Medicines. This designation confirms its critical role in treating various forms of leishmaniasis globally.

Q: How is the need for Glucantime treatment typically confirmed by a healthcare provider?

According to official drug profiles, the administration of treatment must continue until the official clinical endpoint is reached. This endpoint is defined as the disappearance of the parasite in clinical samples taken by a healthcare provider.

Q: Does Glucantime have any known effect on fertility?

Preclinical studies examined the potential impact of the drug on reproduction. Studies in animals suggested that even at high doses, the active substance did not show a significant impact on the development of reproductive functions.

Q: Why is Glucantime not typically prescribed for short-term minor issues?

The drug is officially indicated exclusively for the treatment of various forms of leishmaniasis. This is a specific parasitic infection that requires a defined, often long-term, course of treatment to clear the infection.

Q: What is the official stance on Glucantime use during breastfeeding?

Official product information advises caution. Because it is not currently known whether meglumine antimoniate is passed into breast milk, breast-feeding is not recommended during the course of treatment with Glucantime.

Q: What are the published results of Glucantime research trials?

The published research cited by international health organizations indicates that Glucantime has demonstrated positive outcomes in clinical trials for the officially indicated conditions.

Q: What are the common signs of a serious side effect from Glucantime?

Official regulatory documents include warnings about the potential for serious adverse reactions. These concerns relate to the heart, such as arrhythmia (irregular heartbeat), and risks to the kidneys, such as acute renal failure (sudden kidney damage). Additionally, severe allergic reactions, or hypersensitivity reactions, have been reported.

Q: Is Glucantime a branded product or a generic medication?

Glucantime is a widely recognized brand name for the medicine. The active substance it contains is meglumine antimoniate.

Glucantime solution for injection must be stored according to regulatory requirements to maintain its quality and potency.

Storage Conditions

Requirement	Official Regulatory Statement
Temperature	Store at a temperature below 25°C (77°F).
Protection	The product should be protected from light and must not be frozen.
Stability	The solution must be used immediately after the ampoule is opened.
Child Safety	The medicine must be kept out of the sight and reach of children.

Disposal Instructions

Any unused Glucantime or waste material must be disposed of in accordance with local requirements for pharmaceutical waste. The product must not be disposed of via wastewater or household waste due to the environmental classification of the active substance, as specified in regulatory documentation.